Abemaciclib (Verzenios®). HTA ID: 22020

Assessment Status NCPE Assessment Process complete
HTA ID 22020
Drug Abemaciclib
Brand Verzenios®
Indication in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative, node positive early breast cancer at high risk of recurrence.
Assessment Process
Rapid review commissioned 11/04/2022
Rapid review completed 06/05/2022
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of abemaciclib compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 26/05/2022
Pre-submission consultation with Applicant 26/07/2022
Full submission received from Applicant 28/03/2023
Preliminary review sent to Applicant 06/04/2023
NCPE assessment re-commenced 10/05/2023
Follow-up to preliminary review sent to Applicant 21/06/2023
NCPE assessment re-commenced 29/06/2023
Factual accuracy sent to Applicant 18/08/2023
NCPE assessment re-commenced 25/08/2023
NCPE assessment completed 19/09/2023
NCPE assessment outcome The NCPE recommends that abemaciclib (Verzenios®) be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments*.

Technical Summary

Plain English Summary

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013